Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Among authors: oren i. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Marty FM, et al. Among authors: oren i. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9. Lancet Infect Dis. 2016. PMID: 26969258 Clinical Trial.
Isavuconazole for treatment of rare invasive fungal diseases.
Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Perfect JR, Oren I, Schmitt-Hoffmann AH, Giladi M, Marty FM, Rahav G. Cornely OA, et al. Among authors: oren i. Mycoses. 2018 Aug;61(8):518-533. doi: 10.1111/myc.12778. Mycoses. 2018. PMID: 29611246 Clinical Trial.
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. Wunderink RG, et al. Among authors: oren i. Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1. Infect Dis Ther. 2018. PMID: 30270406 Free PMC article.
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidemia Study Group. Ben-Ami R, et al. Among authors: oren i. Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6. Antimicrob Agents Chemother. 2012. PMID: 22314534 Free PMC article.
Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel.
Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidaemia Study Group. Ben-Ami R, et al. Among authors: oren i. Clin Microbiol Infect. 2013 Aug;19(8):752-6. doi: 10.1111/1469-0691.12004. Epub 2012 Sep 25. Clin Microbiol Infect. 2013. PMID: 23005038 Free article.
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, Gorelik A, Dally N, Zuckerman T, Haddad N, Fineman R, Dann EJ. Oren I, et al. Bone Marrow Transplant. 2006 Jul;38(2):127-34. doi: 10.1038/sj.bmt.1705418. Epub 2006 Jun 5. Bone Marrow Transplant. 2006. PMID: 16751782 Clinical Trial.
Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial.
Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, Raz-Pasteur A, Lavi N, Saad E, Henig I, Horowitz N, Avivi I, Benyamini N, Fineman R, Ofran Y, Haddad N, Rowe JM, Zuckerman T. Oren I, et al. Am J Infect Control. 2013 Dec;41(12):1167-72. doi: 10.1016/j.ajic.2013.04.018. Am J Infect Control. 2013. PMID: 24274912 Clinical Trial.
Campylobacter bacteraemia: 16 years of experience in a single centre.
Hussein K, Raz-Pasteur A, Shachor-Meyouhas Y, Geffen Y, Oren I, Paul M, Kassis I. Hussein K, et al. Among authors: oren i. Infect Dis (Lond). 2016 Nov-Dec;48(11-12):796-9. doi: 10.1080/23744235.2016.1195916. Epub 2016 Jun 20. Infect Dis (Lond). 2016. PMID: 27320494
117 results